First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma
Background . Patients with metastatic or radioactive iodine refractory papillary thyroid carcinoma (PTC) have poor prognosis due to ineffective therapy for this condition beyond surgery and radioactive iodine (RAI or 131 I). BRAF mutation occurs in more than 44% of PCT. Tyrosine kinase inhibitors, t...
Saved in:
Main Authors: | Bao D. Dao MD (Author), Ildiko Lingvay MD, MPH, MSCS (Author), Joseph Sailors MD (Author), Michael Landay MD (Author), Gabriel Shapiro MD, FACP (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2015-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
by: Mary Clark, MD, et al.
Published: (2022) -
Clinical Treatment Efficacy of Total Thyroidectomy Combined with Radioactive Iodine on Treatment of Thyroid Cancer and Its Effect on the Quality of Life of Patients
by: Yong YANG, et al.
Published: (2019) -
Delayed-onset vemurafenib-induced panniculitis
by: Stephen L. Vance, MD, MBA, et al.
Published: (2017) -
The dilemma of managing thyroid gland after incidental diagnosis of malignant struma Ovarii. Is radical thyroidectomy and radioactive iodine Necessary? A case report and literature review
by: Wiktoria Irena Batog, et al.
Published: (2023) -
Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis
by: Anil Sharma, et al.
Published: (2017)